Skip to content

Vera Therapeutics VERA Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
Immunovant, Inc. logo
Immunovant, Inc.IMVT
Alumis Inc. logo
Alumis Inc.ALMS

Other financials

Income statement

See full
Operating income-$125.1M-119%
Net income-$121.0M-134%
EPS (diluted)-$1.69-109%

Balance sheet

See full
Cash & equivalents$114.4M+108%
Total debt$75.0M+37.8%
Total equity$499.7M-6.6%
Total assets$621.7M+1.9%

Cash flow

See full
Operating cash flow-$106.5M-95.8%
CapEx$23.0K-87.7%
Free cash flow-$106.5M-95.1%

Valuation

See full
Market cap$2.74B+87.5%
Enterprise value$2.7B+85.0%

Returns & leverage

See full
Return on equity-71.3%+296pp
Debt / equity0.2×0.0×
Current ratio13.6×-14.0×

Where this comes from

Reported directly by Vera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Vera Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vera Therapeutics's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vera Therapeutics's deferred tax assets and other non-current assets?
Vera Therapeutics (VERA) reported deferred tax assets and other non-current assets of $5.94M in Q1 2026.